AnaptysBio, Inc. Share Price & Technical Analysis
ANAB · $57.57 (-3.58%)
Healthcare / Biotechnology
$57.57
-3.58%
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial …
Price chart
Seasonality
May has 0 positive and 4 negative years (last 5 years shown)
-9% return in May, -3% avg return in past 3 year May month.
85% return in 2026, 40% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -2% | 17% | 3% | 76% | -9% | – | – | – | – | – | – | – | 85% |
| 25 | 35% | -5% | 10% | 19% | 0% | -1% | 12% | -17% | 50% | 20% | 15% | 17% | 155% |
| 24 | 11% | 8% | -12% | 8% | -2% | 3% | 39% | 9% | -12% | -35% | 15% | -44% | -12% |
| 23 | -20% | 0% | -13% | -4% | -9% | 7% | -3% | 0% | -9% | -9% | -13% | 51% | -23% |
| 22 | -9% | -5% | -19% | -6% | -19% | 6% | 3% | 12% | 21% | 12% | -12% | 11% | -4% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Uptrend · Neutral
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.86B
P/E ratio
—
52W high
$72.36
52W low
$11.40
Volume
2,31,719
Beta
0.48
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is AnaptysBio, Inc. share price today?
- AnaptysBio, Inc. (ANAB) last traded around $57.57 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ANAB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ANAB. Download the app for real-time alerts.
- How can I analyze AnaptysBio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.